Core Viewpoint - The announcement details the completion of a share transfer involving 11.04% of Nanjing Pharmaceutical Group Co., Ltd. from Alliance Healthcare Asia Pacific Limited to Guangzhou Guangyao Phase II Fund, with no change in control or significant impact on the company's governance structure [2][3][7]. Group 1: Share Transfer Details - On September 26, 2025, Alliance Healthcare signed a share transfer agreement to sell 144,557,431 shares (11.04% of total shares) to Guangzhou Guangyao Phase II Fund at a price of 5.18 RMB per share, totaling approximately 748.81 million RMB [2][4]. - Following the transfer, Alliance Healthcare no longer holds shares in the company, while Guangzhou Guangyao Phase II Fund now holds the aforementioned shares [2][4]. Group 2: Regulatory Approvals - On November 17, 2025, the company received a notice confirming that Guangzhou Guangyao Phase II Fund obtained approval from its state-owned asset supervisor, Guangzhou Pharmaceutical Group Co., Ltd., for the share acquisition [5]. - The share transfer was officially registered on February 27, 2026, with the transfer date being February 26, 2026, confirming the completion of the transaction [6]. Group 3: Impact and Commitments - The share transfer will not result in a change of the company's controlling shareholder or actual controller, nor will it trigger a mandatory bid or significantly affect the company's governance and ongoing operations [3][7]. - Guangzhou Guangyao Phase II Fund has committed not to transfer the acquired shares for 18 months, except to entities controlled by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., and this commitment also applies to any shares derived from stock dividends or capital increases during this period [7].

关于公司持股 5%以上股东协议转让股份过户完成的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司 2026 年 2 月 27 日，中国证券登记结算有限责任公司出具《证券过户登记确 认书》，本次交易已完成过户登记手续，过户日期为 2026 年 2 月 26 日。本次过 户登记完成后，广药二期基金持有公司 144,557,431 股无限售流通股（占公司目 前总股本的 11.04%）。 重要内容提示： 2025 年 9 月 26 日，南京医药集团股份有限公司（以下简称"公司"）持 股 5% 以上股东 Alliance Healthcare Asia Pacific Limited（以下简称"Alliance Healthcare"）与广州广药二期基金股权投资合伙企业（有限合伙）（以下简称"广 药二期基金"）签署《关于南京医药股份有限公司 11.04%股份的股份转让合同》， 将其持有的全部 144,557,431 股公司股份（以下简称"目标 ...

Core Viewpoint - Alliance Healthcare, a major shareholder of Nanjing Pharmaceutical, has signed a share transfer agreement with Guangzhou Pharmaceutical Phase II Fund to transfer its entire 145 million shares, representing 11.04% of the company, at a price of 5.18 yuan per share, totaling 749 million yuan [1] Group 1 - Alliance Healthcare will no longer hold any shares in Nanjing Pharmaceutical after the transfer [1] - Guangzhou Pharmaceutical Phase II Fund will hold 145 million shares, accounting for 11.04% of the company's total share capital [1] - The share transfer has been confirmed by the China Securities Depository and Clearing Corporation, with the transfer date set for February 26, 2026 [1]

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds amounting to 130 million RMB for cash management by purchasing a structured deposit linked to the Australian dollar against the US dollar through China Minsheng Bank, aiming to enhance fund efficiency and shareholder returns [1][3][8]. Cash Management Overview - The cash management amount is set at 130 million RMB, which will be invested in a structured deposit product from China Minsheng Bank [4][8]. - The funds for this cash management initiative are sourced from temporarily idle raised funds from the issuance of convertible bonds [4][6]. - The company aims to improve the efficiency of temporarily idle raised funds, reduce financial costs, and increase shareholder returns while ensuring that the investment does not affect the normal operation of fundraising projects [3][12]. Previous Cash Management Performance - In a previous cash management initiative, the company redeemed 150 million RMB from a structured deposit with China Minsheng Bank, yielding approximately 587,100 RMB in returns, which met expectations [3]. - A subsidiary, Nanjing Medical Kangjie Logistics, also redeemed 65 million RMB from a structured deposit with Ping An Bank, achieving returns of about 278,500 RMB, which also met expectations [3]. Approval Process - The board of directors convened a temporary meeting on November 20-21, 2025, to approve the continued use of up to 500 million RMB of temporarily idle raised funds for cash management, with a validity period of 12 months from the previous authorization expiration date [9][12]. - The investment products selected are characterized by high safety, good liquidity, and low risk, ensuring that the fundraising projects remain unaffected [9][12]. Impact on Company - The cash management initiative is expected to enhance the efficiency of the use of raised funds without impacting the normal operation of fundraising projects or the company's main business development [12]. - By managing temporarily idle funds effectively, the company aims to achieve better overall performance and provide greater returns for shareholders [12].

Core Viewpoint - Nanjing Pharmaceutical Group Co., Ltd. has announced the use of idle raised funds for cash management, indicating a strategic approach to optimize financial resources while ensuring that investment projects remain unaffected [1]. Group 1: Financial Performance - As of February 26, 2026, Nanjing Pharmaceutical's stock closed at 5.5 yuan, down 0.72% from the previous trading day, with a total market capitalization of 7.199 billion yuan [1]. - The stock opened at 5.56 yuan, reached a high of 5.56 yuan, and a low of 5.47 yuan, with a trading volume of 68.938 million yuan and a turnover rate of 0.97% [1]. Group 2: Cash Management Announcement - The company and its subsidiaries will use 130 million yuan to purchase a structured deposit linked to the Australian dollar against the US dollar, with a term of 90 days, starting on February 26, 2026, and maturing on May 27, 2026 [1]. - The product has a low-risk rating and offers a principal-protected floating return type, which aligns with the company's risk management strategy [1]. - This cash management initiative has been approved by the company's 10th Board of Directors and will be rolled over within 12 months without impacting ongoing investment projects [1]. - Previous cash management efforts have been redeemed on schedule, with returns meeting expectations [1].

| 证券简称：南京医药 | 编号：ls2026-018 | | --- | --- | | 证券代码：600713 | | 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理产品名称：南京医药集团股份有限公司（以下简称"公司"） 本次使用部分暂时闲置募集资金 13,000 万元购买民生银行聚赢汇率-挂钩澳元对 美元汇率看涨二元结构性存款。 履行的审议程序：公司于2025年11月20-21日召开了第十届董事会临时会 议，审议通过了《关于公司及子公司继续使用部分暂时闲置募集资金进行现金管 理的议案》，同意公司及子公司继续使用不超过人民币5亿元（含本数）暂时闲 置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、风险较 低的保本型投资产品。本次现金管理的使用期限自上一授权期限到期日（2026 年1月22日）起12个月内有效，上述额度在使用期限内 ...

| 工 章 台 缔造有远见的商业传奇 | 南京医药集团江丰股权投资基金有限公司 | | 8 查一下 | ー 応用 ▼ | 企业中心 | | --- | --- | --- | --- | --- | --- | | 基本信息 13 | 法律诉讼 | 经营风险 | 经营信息 企业发展 | | 知识产权 F | | 统一社会信用代码 | 91320105MAK64N8390 | 企业各称 | 南京医药集团江丰股权投资基金有限公司 | | | | 法定代表人 | 彭玉萍 凉关联企业 5 | 登记状态 | 存续(在营、开业、在册) | 成立日期 | 2026-02-13 | | | | 注册资本 | 20000万元 | 实缴资本 | | | 组织机构代码 | MAK64N83-9 | 工商注册号 | | 纳税人识别号 | 91320105MAK64I | | 企业集团 | 其他有限责任公司 | 营业期限 | 2026-02-13 至 无固定期限 | 纳税人资质 | | | 人员规模 | - | 参保人数 | | 核准日期 | 2026-02-13 | | 所属地区 | 江苏省南京市建邺区 | 登记机关 | 南京市建邺 ...

Core Viewpoint - The company Frontline Bio has entered into a significant exclusive licensing agreement with GlaxoSmithKline (GSK) to co-develop two small nucleic acid drugs, with a total deal value exceeding $1 billion, which will help improve its cash flow and financial structure [2][5]. Group 1: Licensing Agreement Details - The agreement includes an upfront payment of $40 million and a milestone payment of $13 million, with potential future payments up to approximately RMB 6.55 billion based on successful development and commercialization [2]. - The collaboration will allow Frontline Bio to focus on early development of the drugs, while GSK will handle global clinical development and commercialization [5]. Group 2: Company Background and Financial Situation - Frontline Bio, founded by CEO Xie Dong in 2013, has faced financial difficulties, accumulating losses of over RMB 1.5 billion in the past five years, with cash reserves declining from RMB 527 million in 2023 to RMB 249 million in 2024 [6][11]. - The company’s flagship product, Aikening, has struggled with sales growth despite being the first long-acting HIV-1 fusion inhibitor approved in China [8][11]. Group 3: Focus on Small Nucleic Acid Drugs - Xie Dong has shifted the company’s strategy to focus on small nucleic acid drugs, which are seen as a promising area in the pharmaceutical industry, expanding from rare diseases to chronic conditions [3]. - The company is developing multiple products targeting various conditions, including IgA nephropathy and hyperuricemia, with most projects still in early stages [3][4]. Group 4: Market Context and Competition - The small nucleic acid drug market is becoming increasingly competitive, with nearly 20 approved products globally and several domestic companies also pursuing this area [14]. - Frontline Bio's pipeline is primarily in preclinical development, and the timeline for clinical trials could extend 7-8 years, creating uncertainty regarding future milestone payments [14].

Core Viewpoint - Nanjing Pharmaceutical (600713) held its first extraordinary shareholders' meeting on February 5, 2026, to discuss corporate governance matters, which may have a short-term impact on investor attention [1] Stock Performance - Over the past 7 days (February 5 to February 11, 2026), Nanjing Pharmaceutical's stock price experienced slight fluctuations, with a range of 0.36%, reaching a high of 5.65 yuan on February 6 and a low of 5.50 yuan on February 5. The latest closing price on February 11 was 5.56 yuan, down 0.71% for the day, with a trading volume of approximately 43.24 million yuan and a net outflow of main funds amounting to 452.96 thousand yuan. During the same period, the pharmaceutical commercial sector declined by 0.65%, indicating that the company's stock performance was slightly better than the industry average [2] Institutional Insights - Institutional interest in Nanjing Pharmaceutical is relatively low, with the latest sentiment being neutral and no significant changes in ratings. The fund holding ratio is only 0.03%, and the frequency of institutional research ranks low within the industry. Some analysts noted that the company's historical financial reports show a median level of ROIC (Return on Invested Capital) that is average, necessitating ongoing monitoring of cash flow and debt status [3]

Group 1 - The company announced the payment details for its 2024 first phase medium-term notes, ensuring the process is smooth and timely [1][4] - The payment funds will be transferred to the designated account of the Central Clearing Corporation before the due date, and any changes in the payment route must be notified in advance [1][4] - The company and its board guarantee the accuracy and completeness of the announcement, taking legal responsibility for its content [1][3] Group 2 - The company also announced the payment details for its 2025 fifth phase short-term financing notes, with similar procedures for fund transfer and notification of changes [4][7] - The payment will be made on the due date, with adjustments for public holidays, and the company will not bear losses due to late notifications from bondholders [4][7] - The company reaffirms its commitment to timely and accurate information disclosure as per regulatory requirements [4][6] Group 3 - The company provided contact information for relevant personnel involved in the issuance and management of the bonds, ensuring transparency and accessibility for bondholders [2][5][8] - The management institutions and custodians are clearly identified, facilitating communication regarding the bonds [2][5][8]